Artificial intelligence (AI) is all the rage these days, even in fields like biotech, where long product development cycles mean that cool new tools today might not lead to cash flows for years. In particular, there is a trio of biotechs going all-in on AI, and so far, the hype wave has been excellent for their shareholders.

All three companies I'll discuss have smashed the market's return this year so far. While it's true that they're quite risky and still need to prove that their AI-driven business models are more than vaporware, the early signs look positive, so let's take a look at each.

The idea of Recursion Pharmaceuticals (NASDAQ: RXRX) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify compounds that are good starting points for drug development.

Continue reading

Source Fool.com